1. Long‐term survival with oral azacitidine for patients with acute myeloid leukemia in first remission after chemotherapy: Updated results from the randomized, placebo‐controlled, phase 3 QUAZAR AML‐001 trial. Issue 4 (6th February 2023) Authors: Wei, Andrew H.; Döhner, Hartmut; Sayar, Hamid; Ravandi, Farhad; Montesinos, Pau; Dombret, Hervé; Selleslag, Dominik; Porkka, Kimmo; Jang, Jun‐Ho; Skikne, Barry; Beach, C. L.; Prebet, Thomas; Zhang, George; Risueño, Alberto; Ugidos, Manuel; See, Wendy L.; Menezes, Daniel; Roboz, Gail J. Journal: American journal of hematology Issue: Volume 98:Issue 4(2023) Page Start: E84 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer. (February 2019) Authors: Levy, Benjamin P.; Giaccone, Giuseppe; Besse, Benjamin; Felip, Enriqueta; Garassino, Marina Chiara; Domine Gomez, Manuel; Garrido, Pilar; Piperdi, Bilal; Ponce-Aix, Santiago; Menezes, Daniel; MacBeth, Kyle J.; Risueño, Alberto; Slepetis, Ruta; Wu, Xiaoling; Fandi, Abderrahim; Paz-Ares, Luis Journal: European journal of cancer Issue: Volume 108(2019) Page Start: 120 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. TET2 Overexpression in Chronic Lymphocytic Leukemia Is Unrelated to the Presence of TET2 Variations. (18th February 2014) Authors: Hernández-Sánchez, María; Rodríguez, Ana Eugenia; Kohlmann, Alexander; Benito, Rocío; García, Juan Luis; Risueño, Alberto; Fermiñán, Encarna; De Las Rivas, Javier; González, Marcos; Hernández-Rivas, Jesús-María Other Names: Hernández Rivas José Ángel Academic Editor. Journal: BioMed research international Issue: Volume 2014(2014) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗